{"name":"Jacob Pontoppidan Thyssen","slug":"jacob-pontoppidan-thyssen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Elocon 0.1 % Topical Cream","genericName":"Elocon 0.1 % Topical Cream","slug":"elocon-0-1-topical-cream","indication":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)","status":"marketed"}]}],"pipeline":[{"name":"Elocon 0.1 % Topical Cream","genericName":"Elocon 0.1 % Topical Cream","slug":"elocon-0-1-topical-cream","phase":"marketed","mechanism":"Mometasone furoate is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.","indications":["Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)","Atopic dermatitis","Contact dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1GX0pKQmZsSml5cnp4RTR2dmFYd21yOE9ydF9kbkdnUk5CX3M1YkgtZUpYbHhSYmMxX3VFM2tvR3RxdEdwRENSLUFOOWtaUm9PRnV2S3VTNjNUcGpwS3p4VlZRN3ozb1BTZ2JEV0J1MA?oc=5","date":"2026-01-26","type":"trial","source":"medwatch.com","summary":"Leo Pharma after new study with growth prospects: \"On track to make Anzupgo our biggest product\" - medwatch.com","headline":"Leo Pharma after new study with growth prospects: \"On track to make Anzupgo our biggest product\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZHgtZ2VLcTByMWJmVFo0UlBIdjRPcjBGNk4wSWxnMlpZRDBqemlyMFN3Njh3cGNRc0tDaHZGRy1WajdQQWxNN1Z2dHRnZURNVkFyQ0JpeFNQS0Zjd3B3V3I3elJHd0UzLTg2SExiZllWLXJGWWRsaXhaT2I5LUFvWmV5RGtxZC1iNjV4dVJia3RONjRzVVNJZA?oc=5","date":"2025-07-23","type":"regulatory","source":"Dermatology Times","summary":"Jacob Thyssen, PhD, on Tackling Hard-to-Treat Hand Eczema - Dermatology Times","headline":"Jacob Thyssen, PhD, on Tackling Hard-to-Treat Hand Eczema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9MS2s1REUyX2MzV3BzekNnd3FpVE1GS0lyVDZCVGUtMFRqSU1LVnVEVl9MYjc2RDRVdk1JR0o5N291TURNLWkteXZLbUkzdHU2cE5PQ0J6WjVvZHZONmozYw?oc=5","date":"2025-07-21","type":"pipeline","source":"medwatch.com","summary":"Leo Pharma CSO comments on closure of research department after its new agreement with contract researchers - medwatch.com","headline":"Leo Pharma CSO comments on closure of research department after its new agreement with contract researchers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxONTJyd2VyQU9FTzBUTEdsd0F6akNJV0RPVHg2eWtoSktGcVh0STFHQnI4dFV3UUlYdDhrYnQ2eXN3b1Q1RG9OX3VrRFE3V25KaGlGS2RyTUljdTRSMG5id20yN0ZGUzczRkxudTVDdmU0cU1SR2NTZHhXRE9zUWJ0X2thcE51VnliR0FBRkk4WWxydjNkQTRqYlFMVDVlSDNVVF8xRk4tRkxOZHdMNUx5aXdkOXVEeDFfZzBDMldNckQ5Nk1DMkNiNl82eWxtZnYzSFZPc1RvdjdUWWJNS1E5MlhvbU8?oc=5","date":"2025-05-09","type":"trial","source":"BioSpace","summary":"LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis - BioSpace","headline":"LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQYjVaVjg2Z240X2pxWTJHN2R2U1drNTlhMGlQZDJ5UlFSSW1OX2JlVlhYWjhTRHVpNXdlTXVlS2VvMUNSRjZKWG82cUhRNVJGZEJ0cmpSV0FHSHVEZVRxMWFvT0lUTzNKYVNiWmNNb1BxUzZmdWs5bTdqMTB3eG1yTTdrTW1QTXVuMEVIeVNwLW9GeGNOMGNr?oc=5","date":"2025-05-09","type":"pipeline","source":"drugtopics.com","summary":"Temtokibart Shows Efficacy in Treatment of Atopic Dermatitis - drugtopics.com","headline":"Temtokibart Shows Efficacy in Treatment of Atopic Dermatitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQcHBNS2JGSFdRNUN2VVRSR1VfZlNrdzFIejlQT1NOVDdjamdEQXdVWU1zRHFxMHkwWEo1d0NpclJnc3FHS2pocmNBMkN3VHIxRFl1LU1scWlHZEkxR0pnc0F4WHRFc29RdXZkQmJKaVBpdDQwZHdJQ1ppQ3plZlRjZTZkdEpMaHF4UE5zcDB0cUp5XzN2VV9wQ1ZaUlNXLTVlMWwwRFRTaHdEUTVpYVI0VHZn?oc=5","date":"2025-04-17","type":"pipeline","source":"PMLiVE","summary":"LEO Pharma and the Parker Institute join forces to advance dermatology research - PMLiVE","headline":"LEO Pharma and the Parker Institute join forces to advance dermatology research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5wR20zWmYyMXhsSnlZdDhkUmk4YURlWjFlSk9iekd3cFJ1VFAwaDdXVGhfTldsdThvdUVWZlNiWkRNQlZMSHdBSUlvaGRZVGFKS3hXc3lJYXU2LThRTDVsNjNJZUtXYjhRa3lqZjRtMA?oc=5","date":"2025-04-14","type":"pipeline","source":"medwatch.com","summary":"Leo Pharma seeks new skin disease treatments through three-year agreement with hospital - medwatch.com","headline":"Leo Pharma seeks new skin disease treatments through three-year agreement with hospital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPRktRRTYtb1JFTkhSM3lkUFJXdlhZSWhJRGhWSnFGZXJMN25kNTZyTUpzazBHQlVnd05jZDhJdlE4bklESFp0dG15MjNnZF9mZGtRSlVfb3JIZFl5MW02RzNWajRnSThlX0RrQnpFN0JkVDIxMG4xUTNaMXRQa3E1UVlBS0tJRU5RTmtmbG9MWVZrRTZLcll4MzdNX3RhOVZJSTdGbXdmdWE0TkkwNWtuRGxn?oc=5","date":"2024-03-12","type":"pipeline","source":"Fierce Pharma","summary":"After transformation under new CEO, Leo Pharma touts innovation model and financial progress - Fierce Pharma","headline":"After transformation under new CEO, Leo Pharma touts innovation model and financial progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNMFNXNVI3WmFTLVNiSUx5LVh2YTFvek1LdDd1aWlsZnFOemZJdVpMWTA4Q2tRZE4tc2RKLVlpbUcwcjZJUHlfR0E0VWF6blhxMERLNUg3eC04VWZCNThMT05JYU1JUExLNngyNEZKSXZlVkF0SmFMVGlxYkhmdlVjZDg2dVcwcDZVQkZOQk95TlBHNnFXQjVzZDlLSmFTOXk1TTNBWkxyWUZtTzRDZ2NYcU51UVBkcXprLWx2QWhRbEk4dG11eHNOUGZ6cWZqVThn?oc=5","date":"2023-06-20","type":"pipeline","source":"Via Ritzau","summary":"LEO Pharma announces changes to its Global Leadership Team - Via Ritzau","headline":"LEO Pharma announces changes to its Global Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUEZhYXFrWm00Rkd3QXE3a0g3anlpN2ZBREM1dkpQX3FWek9LOEpUQzFVd0IwdVhlRlRNUjZmeTNYT2V0bzBHQXRaT01hQUliUmNKUVNGejh1SzFzNlVFR0huWkRjN0ZMMDFPM3NDZWJET0dpSFRzWElsMk1nMEFubllya1hBU1BoLS1uekR3?oc=5","date":"2023-03-17","type":"pipeline","source":"statnews.com","summary":"Up and down the ladder: The latest comings and goings - statnews.com","headline":"Up and down the ladder: The latest comings and goings","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}